Steelcase Inc. (SCS) Is At $13.55 Formed Wedge; Last Week Sarepta Therapeutics, Inc. (SRPT) Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 20 have Buy rating, 0 Sell and 7 Hold. Therefore 74% are positive. Sarepta Therapeutics had 116 analyst reports since August 5, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of SRPT in report on Friday, January 19 with “Buy” rating. The company was maintained on Wednesday, August 26 by Roth Capital. The stock has “Neutral” rating by Piper Jaffray on Friday, January 15. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Needham on Wednesday, September 6. The firm earned “Hold” rating on Friday, October 23 by Jefferies. The stock has “Outperform” rating by Leerink Swann on Tuesday, March 13. Bank of America reinitiated the stock with “Buy” rating in Friday, October 23 report. As per Friday, October 2, the company rating was upgraded by Wedbush. SunTrust maintained it with “Buy” rating and $76.0 target in Wednesday, March 7 report. The stock has “Outperform” rating by Credit Suisse on Thursday, September 7. See Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings:

04/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $87 New Target: $91 Maintain
04/05/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $100 New Target: $92 Maintain
03/05/2018 Broker: Oppenheimer Rating: Hold Downgrade
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Old Target: $64 Downgrade
15/03/2018 Broker: SunTrust Rating: Buy New Target: $95.0 Maintain
14/03/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $75 New Target: $95 Maintain
13/03/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $81 New Target: $100 Maintain
13/03/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $79 New Target: $92 Maintain
12/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $83.0 Maintain
12/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $75 New Target: $92 Maintain

Steelcase Inc. (SCS) formed wedge down with $12.74 target or 6.00% below today’s $13.55 share price. Steelcase Inc. (SCS) has $1.58B valuation. The stock decreased 3.90% or $0.55 during the last trading session, reaching $13.55. About 1.24 million shares traded or 103.89% up from the average. Steelcase Inc. (NYSE:SCS) has declined 19.53% since May 8, 2017 and is downtrending. It has underperformed by 31.08% the S&P500.

Since January 4, 2018, it had 0 insider buys, and 4 sales for $453,842 activity. Niemann Jennifer C sold $48,695 worth of stock or 3,500 shares. WEGE PETER M II had sold 7,000 shares worth $94,190 on Thursday, March 29. 8,000 shares valued at $109,661 were sold by Armbruster Sara E on Wednesday, April 25.

Investors sentiment decreased to 1.18 in 2017 Q4. Its down 0.14, from 1.32 in 2017Q3. It turned negative, as 23 investors sold Steelcase Inc. shares while 53 reduced holdings. 34 funds opened positions while 56 raised stakes. 70.66 million shares or 0.11% more from 70.58 million shares in 2017Q3 were reported. Teton Advisors Inc reported 28,880 shares or 0.04% of all its holdings. Wellington Llp stated it has 0.02% in Steelcase Inc. (NYSE:SCS). Meeder Asset Management holds 0% of its portfolio in Steelcase Inc. (NYSE:SCS) for 3,026 shares. Moreover, Deutsche Comml Bank Ag has 0% invested in Steelcase Inc. (NYSE:SCS). Lazard Asset Mgmt Limited Liability Com holds 0% or 5,000 shares. Raymond James & Assocs stated it has 0% in Steelcase Inc. (NYSE:SCS). Geode Capital Limited Company holds 0.01% in Steelcase Inc. (NYSE:SCS) or 1.13M shares. Quantbot L P holds 0.08% or 54,808 shares in its portfolio. California State Teachers Retirement System holds 0% or 134,476 shares. Denali Advisors Ltd has invested 0% in Steelcase Inc. (NYSE:SCS). Green Square Capital Lc has 0.22% invested in Steelcase Inc. (NYSE:SCS). Schwab Charles accumulated 930,691 shares. National Bank Of America De accumulated 0% or 329,806 shares. Royal Bankshares Of Canada stated it has 0% in Steelcase Inc. (NYSE:SCS). Dimensional Fund Advsrs Ltd Partnership stated it has 3.67 million shares or 0.02% of all its holdings.

Among 2 analysts covering Steelcase (NYSE:SCS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Steelcase had 7 analyst reports since September 1, 2015 according to SRatingsIntel. The rating was maintained by Raymond James on Friday, June 23 with “Strong-Buy – Outperform”. The firm has “Strong Buy” rating given on Thursday, March 23 by Raymond James. Seaport Global initiated Steelcase Inc. (NYSE:SCS) on Friday, November 4 with “Neutral” rating. The rating was downgraded by Raymond James on Wednesday, December 23 to “Mkt Perform”. The firm has “Hold” rating by Sidoti given on Wednesday, September 20. The firm has “Buy” rating by Sidoti given on Friday, September 1. On Tuesday, September 1 the stock rating was downgraded by Zacks to “Buy”.

Analysts await Steelcase Inc. (NYSE:SCS) to report earnings on June, 20. They expect $0.15 EPS, 0.00% or $0.00 from last year’s $0.15 per share. SCS’s profit will be $17.50M for 22.58 P/E if the $0.15 EPS becomes a reality. After $0.24 actual EPS reported by Steelcase Inc. for the previous quarter, Wall Street now forecasts -37.50% negative EPS growth.

More important recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Seekingalpha.com which released: “The Market Has Spoken: Buy Sarepta” on May 07, 2018, also Nasdaq.com published article titled: “Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene …”, Nasdaq.com published: “Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” on April 30, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was released by: Benzinga.com and their article: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” with publication date: April 29, 2018.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $5.91 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

Investors sentiment decreased to 1.22 in 2017 Q4. Its down 1.66, from 2.88 in 2017Q3. It dived, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported. Mufg Americas Holding Corp owns 290 shares. Nokota Management L P reported 80,020 shares. Royal Bancorp Of Canada reported 295,322 shares. Lehman Resource reported 7,753 shares. Susquehanna Int Gru Ltd Liability Partnership has invested 0.02% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 21,369 are owned by Dupont Cap Management Corporation. Envestnet Asset has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Tower Research Cap Lc (Trc) stated it has 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Putnam Limited Liability Company holds 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 22,732 shares. The Ohio-based Meeder Asset has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Parametric Associate Lc reported 152,386 shares. Bokf Na accumulated 42,631 shares or 0.07% of the stock. Nomura reported 322,069 shares. Glenmede Tru Na owns 2,300 shares. State Street holds 0.01% or 2.37 million shares in its portfolio.

The stock increased 0.50% or $0.45 during the last trading session, reaching $90.2. About 2.00 million shares traded or 43.89% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since May 8, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: